Provided is a drug containing a liver targeting specific ligand and a thyroid hormone receptor agonist in its structure, which is a new drug structure formed by linking the liver targeting specific ligand with the thyroid hormone receptor agonist through a branched chain, a linker and a linking chain. Thyroid hormone receptors (TRs) are divided into two subtypes, TR-α and TR-β, wherein, TR-β is mainly expressed in liver, and TR-α is mainly expressed in heart, nervous system, etc. In certain embodiments, it is envisaged that the provided drug has the action of liver targeting, can specifically bring the thyroid hormone receptor agonist into liver, without entering heart and other issues, and may thereby avoid side effects caused by the action of the thyroid hormone receptor agonist on other issues, and maintain its therapeutic efficacy in the treatment of lipid metabolism disorders and related complications.

The invention provides methods and tools, for example, glycan arrays, for the analysis of glycans and anti-glycan antibodies. Embodiments of the invention may be used to detect proteins, antibodies, diseases and/or pathogenic agents. In other embodiments, methods of the invention are used to develop or optimize arrays and antibodies.

The invention provides methods and tools, for example, glycan arrays, for the analysis of glycans and anti-glycan antibodies. Embodiments of the invention may be used to detect proteins, antibodies, diseases and/or pathogenic agents. In other embodiments, methods of the invention are used to develop or optimize arrays and antibodies.

The present invention generally relates to the field of detecting and preventing infectious diseases caused by Enterococcus faecalis and/or Enterococcus faecium. More specifically, the invention relates to an Enterococcus faecalis and/or Enterococcus faecium antigen which comprises at least one unit having the following general formula: ##STR00001##

The present invention generally relates to the field of detecting and preventing infectious diseases caused by Enterococcus faecalis and/or Enterococcus faecium. More specifically, the invention relates to an Enterococcus faecalis and/or Enterococcus faecium antigen which comprises at least one unit having the following general formula: ##STR00001##

The present invention relates to methods for the synthesis of fondaparinux and intermediates thereto.

The present invention relates to methods for the synthesis of fondaparinux and intermediates thereto.

The current invention is directed towards compounds of the general formula (I), wherein the integers are defined as follows: R.sup.1 is —(CH.sub.2)nCH(CH.sub.3).sub.2, R.sup.2 is —(CH.sub.2).sub.n+2CH(CH.sub.3).sub.2, G.sup.1 selected from monosaccharides with 4 to 6 carbon atoms, x in the range of from 1.1 to 4, n is a number in the range of from zero to 3. ##STR00001##

The current invention is directed towards compounds of the general formula (I), wherein the integers are defined as follows: R.sup.1 is —(CH.sub.2)nCH(CH.sub.3).sub.2, R.sup.2 is —(CH.sub.2).sub.n+2CH(CH.sub.3).sub.2, G.sup.1 selected from monosaccharides with 4 to 6 carbon atoms, x in the range of from 1.1 to 4, n is a number in the range of from zero to 3. ##STR00001##

Mixtures comprising a mixture of compounds (A), said mixture comprising a mixture of compounds according to the general formula (I) wherein R.sup.1 is C.sub.1-C.sub.4-alkyl, linear or branched, or hydrogen, R .sup.2 is —CH.sub.2CH.sub.2R.sup.1, each G.sup.1 is glucose or xylose, wherein in the range of from 70 to 95% mole-% are glucose and from 5 to 30 mole-% are xylose, the average of x is in the range of from 1.1 to 4.

##STR00001##